Device Trial Radar · NCT07926854
Unipolar Voltage-Guided Substrate Modification Plus Pulsed Field Ablation Pulmonary Vein Isolation Versus Pulmonary Vein Isolation Alone in Persistent Atrial Fibrillation
Last checked: Nov 20, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
294
Planned (sponsor's estimate)
Start
Nov 2026
Primary completion
Dec 2028
Study completion Dec 2029
Sponsor
- Lead sponsor
- China National Center for Cardiovascular DiseasesGovernment (non-federal)
- Sponsor type
- Government (non-federal)
- Collaborators
- Sir Run Run Shaw Hospital; Guangdong Provincial People's Hospital; Affiliated Hospital of Hebei University; Shanxi Cardiovascular Hospital; The University of Hong Kong-Shenzhen Hospital; The Second Hospital of Hebei Medical University; Second Affiliated Hospital of Xi'an Jiaotong University; The Second Affiliated Hospital of Chongqing Medical University
- First posted
- Nov 9, 2026
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (participant)
- Primary purpose
- Treatment
- FDA-regulated device
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
UNI-PFA is a multicenter, randomized, open-label, superiority trial evaluating whether adding unipolar voltage-guided individualized substrate modification to pulsed field ablation (PFA)-based pulmonary vein isolation (PVI) improves outcomes in patients with persistent atrial fibrillation and a left atrial low-voltage area (LVA) burden of at least 10% of the post-PVI left atrial surface area. Participants are randomized 1:1 to PFA-PVI plus individualized substrate modification (homogenization, box isolation, linear ablation, or a combination) or PFA-PVI alone. The primary endpoint is treatment success at 12 months, defined as freedom from documented atrial fibrillation, atrial tachycardia, or atrial flutter lasting more than 30 seconds after a 90-day blanking period while off class I/III antiarrhythmic drugs. Follow-up includes 14-day continuous ECG patch monitoring at 3, 6, and 12 months, symptom-triggered single-lead ECG, and quality-of-life assessments.
Conditions
- Atrial Fibrillation (AF)
Interventions
VARIPULSE Pulsed Field Ablation SystemDevice
Pulsed field ablation catheter and generator used to perform pulmonary vein isolation in both study arms.
Pulmonary Vein IsolationProcedure
Pulsed field ablation-based pulmonary vein antral isolation with confirmation of entrance and exit block in all pulmonary veins; performed in both arms.
Individualized Substrate ModificationProcedure
Unipolar voltage-guided individualized substrate modification selected according to low-voltage area location, including homogenization, box isolation, linear ablation, or a combination. Performed in the experimental arm only.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Treatment Success at 12 Months After the Index Ablation ProcedureTime frame: 12 months after the index ablation procedure
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Fuwai Hospital, Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.